SEARCH

SEARCH BY CITATION

References

  • 1
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290(2):199206.
  • 2
    Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69e171.
  • 3
    Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85151.
  • 4
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):29812997.
  • 5
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895906.
  • 6
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):20222031.
  • 7
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):25602572.
  • 8
    Douglas JG. Clinical guidelines for the treatment of hypertension in African Americans. Am J Cardiovasc Drugs. 2005;5(1):16.
  • 9
    Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646661.
  • 10
    Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):11051187.
  • 11
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):27612788.
  • 12
    Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):6975.
  • 13
    Rosenstock J, Rossi L, Lin CS, et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther. 1998;23(6):433440.
  • 14
    Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006;8(12):850857.
  • 15
    Franklin S, Lapuerta P. Early reduction of exposure to severe blood pressure levels with irbesartan/HCTZ as first-line treatment of severe hypertension. Presented at: 16th Meeting of the European Society of Hypertension; June 1216, 2006; Madrid, Spain.
  • 16
    Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999;12(8, pt 1):797805.
  • 17
    Howe P, Phillips P, Saini R, et al. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999;21(8):13731396.
  • 18
    Raskin P, Guthrie R, Flack J, et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens. 1999;13(10):683687.
  • 19
    Coca A, Calvo C, Sobrino J, et al. Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther. 2003;25(11):28492864.
  • 20
    Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005;7(10):578586.
  • 21
    Sowers JR, Neutel JM, Saunders E, et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006;8(7):470480.
  • 22
    Ofili E, Nesbitt S, Bhaumik A, et al. Initial therapy with irbesartan/hydrochlorothiazide in black patients with severe hypertension. Presented at: National Medical Association 2007 Annual Convention and Scientific Assembly; August 49, 2007; Honolulu, HI.
  • 23
    Lapuerta P. Irbesartan/HCTZ as initial treatment in patients with moderate hypertension. Presented at: 16th Meeting of the European Society of Hypertension; June 1216, 2006; Madrid, Spain.
  • 24
    Neutel JM, Bhaumik A, Ptaszynska A, et al. Efficacy and safety of irbesartan/hydrochlorothiazide as initial therapy in subgroups of patients with moderate to severe hypertension at high cardiovascular risk. Presented at: 17th Scientific Meeting of the European Society of Hypertension (ESH), June 1519, 2007; Milan, Italy. Abstract 242.
  • 25
    Coca A, Calvo C, Garcia-Puig J, et al. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorizacion Ambulatoria Presion Arterial APROVEL). Clin Ther. 2002;24(1):126138.
  • 26
    Littlejohn T II, Saini R, Kassler-Taub K, et al. Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. Clin Exp Hypertens. 1999;21(8):12731295.
  • 27
    Reeves RA, Lin CS, Kassler-Taub K, et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension. 1998;31(6):13111316.
  • 28
    Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998;12(3):203208.
  • 29
    Neutel J. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. Presented at: 16th meeting of the European Society of Hypertension; June 1216, 2006; Madrid, Spain.
  • 30
    Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2007 Oct 11;[Epub ahead of print].
  • 31
    Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
  • 32
    Weir M, Neutel J, Bhaumik A, et al. Irbesartan/hydrochlorothiazide fixed-dose combination is effective and well tolerated in moderate to severe (Stage 2) hypertensive patients with and without advanced age, obesity, and/or type 2 diabetes. Presented at: 22nd Meeting of the American Society of Hypertension; May 1922, 2007; Chicago, IL.